Presentation of Translational Type 2 Diabetes Research

The focus of the research group is to understand the pathophysiological and molecular disease mechanisms responsible for the development of type 2 diabetes. The aim is to contribute to a better prevention, prediction and treatment of the disease.

​The research field

Our research is based on human studies of people with type 2 diabetes as well as people at risk of developing the disease. Our studies involve both very detailed physiological studies of smaller groups of subjects, often in combination with various lifestyle interventions, as well as larger but less detailed epidemiological studies of up to several thousands of subjects. 

The research group has a special interest in the area of fetal programming of type 2 diabetes as a result of either fetal malnutrition or due to the mother having diabetes in pregnancy.

The group has over the years contributed to our current understanding of type 2 diabetes as being extremely heterogenous, including both a multifactorial aetiology, as well as multiple a multiple organ pathophysiology with metabolic defects in many different organs including pancreas, liver, adipose tissue, skeletal muscle, intestines etc.

The ambition / strategic focus / vision / goal - a section describing what you want to achieve, what can your research contribute to?  To Whom / What Does It Mean to them? 

Strategic focus

Our long-term goal is prevention and/or cure of type 2 diabetes. Our focus on how environmental versus hereditary (genetic) aetiological factors in a differential manner affect physiological and molecular functions of glucose metabolism in different organs. Our research focus on improving understanding of distinct type 2 diabetes subgroups with different needs for (individualized) prevention and treatment of the disease. 

Our disease mechanism research may lead to the identification of new biomarkers to predict disease progression, prognosis and/or treatment response, as well as to the development of novel precision medicines for the treatment of type 2 diabetes.

Our research on the importance of the fetal environment can lead to a more sustainable prevention of type 2 diabetes across generations. Our participation in the Innovation Fund project TRANSLATE will ensure that individual type 2 diabetes patients benefits immediately from current and emerging breakthroughs in genomic research. 


Team 1: Fetal programming pathophysiology (team leader Charlotte Brøns).
Team 2: Clinical Intervention Research (team leader Tina Vilsbøll). 


  • Lund University Diabetes Center, Malmø, Sweden
  • Advent Health Research Institute, Orlando, FL, USA
  • Danish Centre for Strategic Research in type 2 diabetes (DD2)
  • Frederiksberg Hospital, Center for Clinical Research and Prevention 
  • Rigshospitalet, Department of Cardiology, Obstetrics and Endocrinology
  • Rigshospitalet, Center for Active Health (CFAS)
  • University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research

Responsible editor